These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34295832)

  • 1. Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against
    Gamba JC; Roldán C; Prochetto E; Lupi G; Bontempi I; Poncini CV; Vermeulen M; Pérez AR; Marcipar I; Cabrera G
    Front Cell Infect Microbiol; 2021; 11():671104. PubMed ID: 34295832
    [No Abstract]   [Full Text] [Related]  

  • 2. Trans-sialidase-based vaccine candidate protects against
    Prochetto E; Roldán C; Bontempi IA; Bertona D; Peverengo L; Vicco MH; Rodeles LM; Pérez AR; Marcipar IS; Cabrera G
    Oncotarget; 2017 Aug; 8(35):58003-58020. PubMed ID: 28938533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal immunization with a L. lactis-derived trans-sialidase antigen plus c-di-AMP protects against acute oral T. cruzi infection.
    Pacini MF; González FB; Dinatale B; Bulfoni Balbi C; Villar SR; Farré C; Lupi G; Espariz M; Blancato VS; Magni C; Marcipar I; Pérez AR
    Vaccine; 2022 Apr; 40(15):2311-2323. PubMed ID: 35279330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of myeloid-derived suppressor cells during Trypanosoma cruzi infection.
    Borgna E; Prochetto E; Gamba JC; Marcipar I; Cabrera G
    Int Rev Cell Mol Biol; 2023; 375():117-163. PubMed ID: 36967151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines and the regulatory arm of the immune system. An overview from the Trypanosoma cruzi infection model.
    Cabrera G; Marcipar I
    Vaccine; 2019 Jun; 37(28):3628-3637. PubMed ID: 31155420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-Derived Suppressor Cells in
    Fresno M; Gironès N
    Front Cell Infect Microbiol; 2021; 11():737364. PubMed ID: 34513737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
    Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
    Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
    Front Immunol; 2019; 10():1456. PubMed ID: 31293599
    [No Abstract]   [Full Text] [Related]  

  • 9. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge.
    Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR
    Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.
    Katae M; Miyahira Y; Takeda K; Matsuda H; Yagita H; Okumura K; Takeuchi T; Kamiyama T; Ohwada A; Fukuchi Y; Aoki T
    Infect Immun; 2002 Sep; 70(9):4833-40. PubMed ID: 12183527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
    Vasconcelos JR; Hiyane MI; Marinho CR; Claser C; Machado AM; Gazzinelli RT; Bruña-Romero O; Alvarez JM; Boscardin SB; Rodrigues MM
    Hum Gene Ther; 2004 Sep; 15(9):878-86. PubMed ID: 15353042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.
    Prochetto E; Bontempi I; Rodeles L; Cabrera G; Vicco M; Cacik P; Pacini MF; Pérez Gianeselli M; Pérez AR; Marcipar I
    Acta Trop; 2022 May; 229():106334. PubMed ID: 35101415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
    Haolla FA; Claser C; de Alencar BC; Tzelepis F; de Vasconcelos JR; de Oliveira G; Silvério JC; Machado AV; Lannes-Vieira J; Bruna-Romero O; Gazzinelli RT; dos Santos RR; Soares MB; Rodrigues MM
    Vaccine; 2009 Sep; 27(41):5644-53. PubMed ID: 19635607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
    Fontanella GH; De Vusser K; Laroy W; Daurelio L; Nocito AL; Revelli S; Contreras R
    Vaccine; 2008 May; 26(19):2322-34. PubMed ID: 18403070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.
    Bontempi I; Leal K; Prochetto E; Díaz G; Cabrera G; Bortolotti A; Morbidoni HR; Borsuk S; Dellagostin O; Marcipar I
    Clin Exp Immunol; 2020 Sep; 201(3):306-316. PubMed ID: 32464684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain.
    Vasconcelos JR; Boscardin SB; Hiyane MI; Kinoshita SS; Fujimura AE; Rodrigues MM
    Immunol Cell Biol; 2003 Apr; 81(2):121-9. PubMed ID: 12631235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
    Basso B; Marini V
    Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
    Chowdhury IH; Lokugamage N; Garg NJ
    Front Immunol; 2020; 11():595039. PubMed ID: 33414785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.